Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Acquisitions & Divestments (2024 - 2025)

Immunome's Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $125.0 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 316.67% year-over-year to $125.0 million; the TTM value through Dec 2025 reached $200.0 million, changed N/A, while the annual FY2025 figure was $200.0 million, 29.03% up from the prior year.
  • Change in Acquisitions & Divestments reached $125.0 million in Q3 2025 per IMNM's latest filing, up from $60.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $125.0 million in Q3 2025 to a low of $15.0 million in Q1 2025.